



Third Quarter and First Nine Months 2023 Financial Results and Business Update

November 14, 2023



Alexander Zehnder

Business Update

Chief Executive Officer



Myriam Mendila

Program Update

Chief Development Officer



Pierre Kemula

Financial Update

Chief Financial Officer



Marcus Dalton

Q&A Session

Head of Intellectual Property

Forward-Looking Statements



The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Prophylactic Vaccines

Phase 2 COVID-19

- ✓ Study **completed enrollment** at 427 participants
- ✓ Assessing mono- (**CV0601**) and bivalent (**CV0701**) candidates
- Data expected in **early in 2024**

Phase 2 Seasonal Flu

- ✓ **Dosing of first participant** initiated Phase 2 of combined Phase 1/2 study
- ✓ Assessing **multivalent candidate** encoding all WHO recommended strains
- Data expected in **2024**

Oncology

- ✓ **Phase 1 in glioblastoma** on track – **third dose level** opened with multi-epitope cancer vaccine candidate **CVGBM**

Manufacturing

- ✓ **The RNA Printer®** achieved first **manu-facturing license** for mRNA construct to support **oncology strategy**

Finance

€464.1 million

- ✓ Cash position as of September 30, 2023
Confirming runway to mid-2025

Intellectual Property Rights

Germany

- ✓ **Infringement position substantiated:** court postpones ruling on four IP rights until validity has been determined
- Next validity milestone: **Ruling** for '122 patent on **December 19**
- Next infringement milestone: **Ruling** for '122 patent on **December 28**

United States

- ✓ **Litigation trial date set:** jury trial on October 1, 2024, before the District Court for the Eastern District of Virginia

CureVac Pipeline: A Diversified Portfolio



AREA	PROGRAM		CANDIDATE	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	
PROPHYLACTIC VACCINES	2 nd -Generation	COVID-19	GSK	CV0601 / CV0701	(modified mRNA)			
		Influenza		Multivalent construct	(modified mRNA)			
	2 nd -Generation	Other	GSK	Four undisclosed targets				
	1 st -Generation	Rabies		CV7202				
	Diverse Projects		BILL & MELINDA GATES foundation	Rota, malaria, universal influenza				
ONCOLOGY	Surgically resected glioblastoma			CVGBM	(unmodified mRNA)			
	Solid tumors ¹⁾			CV8102				
	Neoantigens			Antigen discovery engine based on new technologies acquired with Frame Cancer Therapeutics				
	Tumor Associated Antigens							
MOLECULAR THERAPY	Cas9 gene-editing			CRISPR Therapeutics collaboration				
	Liver Diseases			REBIRTH-Research Center collaboration				
	Ocular Diseases			Schepens Eye Research Institute collaboration				
	Therapeutic Antibodies				Genmab collaboration			

Phase 2 Study COVID-19



Phase 2 Part Seasonal Flu

- **CV0601**, monovalent candidate encoding the spike protein of BA.4-5
- **CV0701**, bivalent candidate encoding the spike protein of BA.4-5 and the original SARS-CoV-2 strain
- Licensed bivalent mRNA **comparator vaccine**
- Study **fully enrolled** at 427 participants
- Data expected in **early 2024**
- Study conducted in **Australia**

- Candidate selected from **comprehensive Phase 1 part** of combined study
- Licensed age-appropriate **comparator vaccines**
- Candidate encodes antigens matched to all **WHO-recommended flu strains**
- Data expected in **2024**
- **Exp. 960** participants in Phase 2 part
- Study conducted in the **U.S., Belgium, Canada** and **South Africa**



Phase 2 Study COVID-19

427 participants
aged 18 and older

Bivalent candidate
Omicron BA.4-5
and wild type

CV0701 higher dose

CV0701 medium dose

CV0701 lower dose

**Licensed bivalent
mRNA comparator**

Monovalent candidate
Omicron BA.4-5

CV0601 medium dose

Phase 2 Part Seasonal Flu

Exp. 480 younger adults
aged 18-64

Exp 480 older adults
aged 65-85

Candidate dose 1

Candidate dose 1

Candidate dose 2

Candidate dose 2

Candidate dose 3


Candidate dose 3

**Licensed comparator
younger adults**

**Licensed comparator
older adults**

Phase 1 Study in Glioblastoma Leverages Clinically Validated Shared Antigens

CVGBM: Multi-Epitope mRNA Construct



Phase 1 Clinical Study

Part A

Exp. 15-24 patients

CVGBM 100 µg

CVGBM 50 µg



CVGBM 25 µg



CVGBM 12 µg



Part B


Exp. ca. 20 patients

Dose expansion

At recommended dose

In Vivo Validation of CureVac's Multiepitope Cancer Vaccine Design

Ten B16.F10 murine melanoma-derived epitopes




B16.F10 murine tumor model:


- Check-point inhibitor resistant model
- Immune-suppressing microenvironment
- Poorly immunogenic tumors

Immunogenicity in mice across full multiepitope construct²⁾

Day 21: strong CD8⁺ T cell responses against **five** encoded epitopes




Day 21: strong CD4⁺ T cell response against **two** encoded epitopes



Efficacy in tumor bearing mice²⁾

Significantly extended survival from a median of **23.2 days** to **30.9 days**



■ B16 mRNA construct ■ Control mRNA ■ Untreated

The RNA Printer® Progressing in Regulatory Review With Initial Milestone



The RNA Printer®

- Highly automated end-to-end system
- Manufacturing of GMP-grade mRNA vaccines and therapeutics
- Closes small-scale manufacturing gap
- Integral part of CureVac's oncology strategy

First regulatory milestone achieved:


Manufacturing license for mRNA construct



DNA module



RNA module



Formulation
module

Ongoing regulatory review for extended licenses



Intellectual Property Rights - By Type

Patents at issue

	Grant date	Expiry date
1. EP 1 857 122 B1	Dec 1, 2010	Jun 5, 2022
2. EP 3 708 668 B1	Jul 27, 2022	Dec 11, 2035
3. EP 4 023 755 B1	Apr 26, 2023	Dec 11, 2035

Utility Models at issue

	Grant date	Expiry date
4. DE 20 2015 009 961 U1	Jan 25, 2021	Dec 11, 2025
5. DE 20 2015 009 974 U1	Feb 17, 2022	Dec 11, 2025
6. DE 20 2021 003 575 U1	Jan 17, 2022	Feb 3, 2031
7. DE 20 2021 004 123 U1	Oct 26, 2022	Feb 3, 2031
8. DE 20 2021 004 130 U1	Oct 26, 2022	Feb 3, 2031

Intellectual Property Rights - By Patent Family

<p>1. G/C Enrichment (Foundational mRNA technology)</p>	<p>EP 1 857 122 B1</p>
<p>2. Split Poly-A Tail (Foundational mRNA technology)</p>	<p>EP 3 708 668 B1 EP 4 023 755 B1 DE 20 2015 009 961 U1 DE 20 2015 009 974 U1</p>
<p>3. Coronavirus vaccine (SARS-CoV-2 vaccine design)</p>	<p>DE 20 2021 003 575 U1 DE 20 2021 004 123 U1 DE 20 2021 004 130 U1</p>

Bifurcated German Process to Assess Infringement and Validity Per IP Right



Infringement proceedings

Regional Court Düsseldorf
All IP rights

Public Hearing

Infringement ruling

Timelines vary per IP right

Potential appeal

Damages proceedings

Regional Court Düsseldorf
All IP rights

Each intellectual property right is handled as a separate case for all proceedings

Validity proceedings

European Patent Office
EP 3 708 668 B1 EP 4 023 755 B1

German Federal Patent Court
EP 1 857 122 B1

German Patent and Trademark Office
DE 20 2015 009 961 U1 DE 20 2021 004 123 U1
DE 20 2015 009 974 U1 DE 20 2021 004 130 U1
DE 20 2021 003 575 U1

Validity ruling

Timelines vary per IP right

Potential appeal

Defending CureVac's Intellectual Property in Germany



Infringement

Regional Court Düsseldorf First ruling, Sep 28

EP 3 708 668 B1 DE 20 2015 009 961 U1
DE 20 2015 009 974 U1
DE 20 2021 003 575 U1

Regional Court Düsseldorf First ruling, Dec 28

EP 1 857 122 B1

Regional Court Düsseldorf Hearing, Aug 15

EP 3 708 668 B1 DE 20 2015 009 961 U1
EP 1 857 122 B1 DE 20 2015 009 974 U1
DE 20 2021 003 575 U1

Regional Court Düsseldorf Hearing, Sep 10

EP 4 023 755 B1
DE 20 2021 004 123 U1
DE 20 2021 004 130 U1

Regional Court Düsseldorf IP right addition, Jul 12

EP 4 023 755 B1 DE 20 2021 004 123 U1
DE 20 2021 004 130 U1

Potential damages trial

Potential appeal

2023



2024



European Patent Office Exp. First ruling

EP 3 708 668 B1

Validity

German Federal Patent Court Positive prelim. opinion, Apr 6

EP 1 857 122 B1

German Federal Patent Court First ruling, Dec 19

EP 1 857 122 B1




Intellectual Property Rights

Patents at issue	Grant date	Expiry date
1. US 11 135 312 B2	Oct 5, 2021	Feb 10, 2026
2. US 11 149 278 B2	Oct 19, 2021	Feb 2, 2036
3. US 11 286 492 B2	Mar 29, 2022	Dec 11, 2035
4. US 11 345 920 B2	May 31, 2022	Dec 11, 2035
5. US 11 241 493 B2	Sep 1, 2020	Jul 10, 2036
6. US 11 471 525 B2	Feb 8, 2022	Feb 3, 2041
7. US 11 576 966 B2	Oct 18, 2022	Feb 3, 2041
8. US 11 596 686 B2	Feb 14, 2023	Feb 3, 2041
9. US 10 760 070 B2	Mar 7, 2023	Feb 3, 2041
10. US 11 667 910 B2	Jun 6, 2023	May 30, 2036

Intellectual Property Rights - By Invention

1. G/C Enrichment <i>(Foundational mRNA technology)</i>	US 11 135 312 B2
2. Split Poly-A Tail <i>(Foundational mRNA technology)</i>	US 11 149 278 B2 US 11 286 492 B2 US 11 345 920 B2
3. Coronavirus Vaccine <i>(SARS-CoV-2 vaccine design)</i>	US 11 241 493 B2 US 11 471 525 B2 US 11 576 966 B2 US 11 596 686 B2
4. Filtration <i>(Purification manufacture)</i>	US 10 760 070 B2 US 11 667 910 B2

Defending CureVac's Intellectual Property in the U.S.



Cash and Condensed Consolidated P&L Data



	December 31, 2022	September 30, 2023
(in € millions)		
Cash and Cash Equivalents	495.8	464.1

	Three months ended September 30,		Nine month ended September 30,	
(in € millions)	2022	2023	2022	2023
Revenue	11.2	16.5	55.7	31.2
Cost of Sales, Operating Expenses & Other Operating Income	-63.6	-70.5	-183.6	-217.4
Operating Result	-52.4	-54.0	-127.9	-186.2
Financial Result	4.7	5.3	7.5	12.7
Pre-Tax Loss	-47.7	-48.7	-120.4	-173.5



Delivering across our strategic priorities in 2023 with clinical lead programs in **COVID-19** and **flu** in **Phase 2** of clinical development and successfully advancing oncology **Phase 1** study in **glioblastoma**



Going into 2024 expecting **ongoing execution** driven by **key data** from three clinical programs, clinical Phase 3 developments in infectious diseases and improved **organizational efficiency**



Progressing toward seeking **recognition** of our intellectual property rights and claim to **fair compensation** to invest into new transformative mRNA-based medicines



Strong cash position of **€464.1** million for executing on programs and priorities in 2024 and into mid-2025 will be accompanied by disciplined focus on **cost management**





**Thank you for your
attention**

CureVac
www.curevac.com